The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
Abstract
Purpose: To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and Methods: Efficacy data from a large randomized phase III study of GC versus MVAC were updated. Time-to-event analyses were performed on the observed distributions of overall and progression-free survival. Results: A total of 405 patients were randomly assigned: 203 to the GC arm and 202 to the MVAC arm. At the time of analysis, 347 patients had died (GC arm, 176 patients; MVAC arm, 171 patients). Overall survival was similar in both arms (hazard ratio [HR], 1.09; 95% CI, 0.88 to 1.34; P = .66) with a median survival of 14.0 months for GC and 15.2 months for MVAC. The 5-year overall survival rates were 13.0% and 15.3%, respectively (P = .53). The median progression-free survival was 7.7 months for GC and 8.3 months for MVAC, with an HR of 1.09. The 5-year progression-free survival rates were 9.8% and 11.3%, respectively (P = .63). Significant prognostic factors favoring overall survival included performance score (> 70), TNM staging (M0 v M1), low/normal alkaline phosphatase level, number of disease sites (≤ three), and the absence of visceral metastases. By adjusting for these prognostic factors, the HR was 0.99 for overall survival and 1.01 for progression-free survival. The 5-year overall survival rates for patients with and without visceral metastases were 6.8% and 20.9%, respectively. Conclusion: Long-term overall and progression-free survival after treatment with GC or MVAC are similar. These results strengthen the role of GC as a standard of care in patients with locally advanced or metastatic TCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Self-citationLoehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., Herr, H., Higgins, G., & Boyle, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3173 · Cited by 728
Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Ahmed, T., Weiselberg, L. R., Geller, N., Hollander, P. S., Herr, H. W., Sogani, P. C., et al. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)48996-8 · Cited by 654
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Robinson, P., von der Maase, H., Bhalla, S., Kielhorn, A., Aristides, M., Brown, A., & Tilden, D. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.1.27 · Cited by 20
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
Witjes, J. A., Compérat, E., Cowan, N. C., De Santis, M., Gakis, G., Lebret, T., Ribal, M. J., Van der Heijden, A. G., & Sherif, A. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.046 · Cited by 1,002
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), T. E. O. F. R. A. T. O. C. G.-U. T. C. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3139 · Cited by 949
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30230-0 · Cited by 786
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
Stenzl, A., Cowan, N. C., De Santis, M., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.023 · Cited by 677
The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer
Stenzl, A., Cowan, N. C., De Santis, M., Jakse, G., Kuczyk, M. A., Merseburger, A. S., Ribal, M. J., Sherif, A., & Witjes, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.01.002 · Cited by 639
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chang, S., Downs, T. M., Efstathiou, J. A., Friedlander, T., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0011 · Cited by 626
Paner, G. P., Stadler, W. M., Hansel, D. E., Montironi, R., Lin, D. W., & Amin, M. B. (2018) · European Urology · doi:10.1016/j.eururo.2017.12.018 · Cited by 621
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309863 · Cited by 511
Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J.-L., De Giorgi, U., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30541-6 · Cited by 501
Self-citationYin, M., Joshi, M., Meijer, R. P., Glantz, M., Holder, S., Harvey, H. A., Kaag, M., Fransen van de Putte, E. E., Horenblas, S., & Drabick, J. J. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0440 · Cited by 474
Bellmunt, J., Choueiri, T. K., Fougeray, R., Schutz, F. A. B., Salhi, Y., Winquist, E., Culine, S., von der Maase, H., Vaughn, D. J., & Rosenberg, J. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4599 · Cited by 450
Self-citationSternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., Théodore, C., Leahy, M. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71160-x · Cited by 389
Self-citationHussain, M. H. A., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Chatta, G. S., Nanus, D. M., Glode, L. M., Trump, D. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0994 · Cited by 376
The effect of age and gender on bladder cancer: a critical review of the literature
Shariat, S. F., Sfakianos, J. P., Droller, M. J., Karakiewicz, P. I., Meryn, S., & Bochner, B. H. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09076.x · Cited by 371
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu223 · Cited by 335
Dogliotti, L., Cartenì, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., Amadori, D., Onat, H., & Marini, L. (2007) · European Urology · doi:10.1016/j.eururo.2006.12.029 · Cited by 330
Self-citationDistinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer
Catto, J. W. F., Miah, S., Owen, H. C., Bryant, H., Myers, K., Dudziec, E., Larré, S., Milo, M., Rehman, I., Rosario, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0744 · Cited by 329
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
Clark, P. E., Agarwal, N., Biagioli, M. C., Eisenberger, M. A., Greenberg, R. E., Herr, H. W., Inman, B. A., Kuban, D. A., Kuzel, T. M., Lele, S. M., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0059 · Cited by 317
Mowatt, G., Zhu, S., Kilonzo, M., Boachie, C., Fraser, C., Griffiths, T., N'Dow, J., Nabi, G., Cook, J., & Vale, L. (2010) · Health Technology Assessment · doi:10.3310/hta14040 · Cited by 313
Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 299
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Cathomas, R., Lorch, A., Bruins, H. M., Compérat, E. M., Cowan, N. C., Efstathiou, J. A., Fietkau, R., Gakis, G., Hernández, V., Espinós, E. L., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.09.026 · Cited by 295
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L.-M., Cookson, M. S., Jacobsen, N.-E., Gandhi, N. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.007 · Cited by 294
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., et al. (2016) · Nature Genetics · doi:10.1038/ng.3692 · Cited by 294
Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., He, Z., Yu, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2488 · Cited by 284
Teo, M. Y., Bambury, R. M., Zabor, E. C., Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2520 · Cited by 280
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., Downs, T. M., Efstathiou, J. A., Flaig, T. W., Friedlander, T., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0156 · Cited by 268
Dash, A., Pettus, J. A., Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Russo, P., Boyle, M. G., Milowsky, M. I., & Bajorin, D. F. (2008) · Cancer · doi:10.1002/cncr.23848 · Cited by 258
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Chen, M.-C., Hsu, W.-L., Hwang, P.-A., Chen, Y.-L., & Chou, T.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.9958 · Cited by 69
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes · doi:10.3390/genes12020260 · Cited by 28
Inoue, S., Sassa, N., Kato, T., Yamauchi, Y., Hirabayashi, T., Yuguchi, Y., Maeda, M., Soeda, Y., Hattori, R., & Gotoh, M. (2020) · International Journal of Urology · doi:10.1111/iju.14367 · Cited by 11
Metadata
- Authors
- von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-07-20
- Volume
- 23
- Issue
- 21
- Pages
- 4602-4608
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103257412
- Cited by
- 1,850
- References
- 7
- FWCI
- 35.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.